Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market: Industry Expert View on Future Growth and Market Trends

Fluorescence in situ hybridization (FISH) is a molecular technique for cytogenetic analysis. This technique uses fluorescent probes that bind to only particular parts of a nucleic acid sequence with a high degree of sequence complementarity. FISH detects the presence or absence of specific DNA sequences on chromosomes. FISH is often used to find specific features in DNA/RNA targets for medicine, genetic counseling, and species identification.

The fluorescence in-situ hybridization (FISH) imaging systems market is majorly comprised of top players involving Euroclone SpA, TissueGnostics GmbH, Agilent Technologies Inc, Abnova Taiwan Corp, BioGenex Laboratories Inc, Leica Biosystems Nussloch GmbH, MetaSystems Probes GmbH, Bio-View Ltd, Thermo Fisher Scientific Inc, Applied Spectral Imaging, and PerkinElmer Inc.

The companies listed above are implementing various strategies that have resulted in the growth of the company and in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position. Below is the list of the growth strategies done by the players operating in the fluorescence in-situ hybridization (FISH) imaging systems market:

Apr-2023: Agilent Technologies Inc had signed a memorandum of understanding with Theragen Bio in South Korea. As part of the partnership agreement, Agilent and Theragen Bio combined their respective strengths in cancer genomic profiling design, engineering knowledge and software expertise to drive localized analysis capabilities and accelerate treatment decisions

Mar-2023: Agilent Technologies Inc had acquired e-MSion. Agilent had worked closely with e-MSion for several years and had offered the company’s ExD cell technology with its 6500 series since 2019

Jan-2023: Thermo Fisher Scientific Inc, the world leader in serving science, had completed its acquisition of The Binding Site Group, a global leader in specialty diagnostics, from a shareholder group led by Nordic Capital in an all-cash transaction valued at GBP 2.3 billion, or US$ 2.8 billion at current exchange rates. The Binding Site adds pioneering innovation in diagnosis and monitoring for multiple myeloma to the existing specialty diagnostics portfolio. Early detection and informed treatment decisions can substantially impact patient outcomes

Dec-2021: BioGenex Laboratories Inc had launched three new primary immunohistochemistry (IHC) antibodies for cancer diagnostics, which includes CD8A, CD56, and CD163

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Chemicals and Materials.

Comments

Popular posts from this blog

Hair Transplant Market: Industry Expert View on Future Growth and Market Trends

Pens Market: Industry Expert View on Future Growth and Market Trends

Hydrocephalus Shunts Market: Industry Expert View on Future Growth and Market Trends